Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
Priya RastogiHanna BandosPeter C LucasLaura van 't VeerJia-Perng J WeiCharles E GeyerLouis FehrenbacherStephen K L ChiaAdam M BrufskyJanice M WalsheGamini S SooriShaker R DakhilSoonmyung PaikSandra M SwainAndrea R MenicucciM William AudehNorman WolmarkEleftherios P P MamounasPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The primary hypothesis of predictive ability of MP on DR was not confirmed. However, the secondary outcomes demonstrated MP was predictive of ELT response and identified a subset of patients with early-stage hormone receptor-positive BC (MP-LR) with improved outcomes from ELT. These data could have important clinical implications in patient selection beyond clinical risk assessment for EET.
Keyphrases
- early stage
- risk assessment
- clinical trial
- palliative care
- study protocol
- high throughput
- case report
- phase iii
- copy number
- genome wide
- human health
- heavy metals
- big data
- phase ii
- stem cells
- editorial comment
- sentinel lymph node
- randomized controlled trial
- type diabetes
- genome wide identification
- open label
- radiation therapy
- early breast cancer
- adipose tissue
- artificial intelligence
- data analysis
- climate change
- insulin resistance
- neoadjuvant chemotherapy
- glycemic control
- genome wide analysis